Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
Date: Thursday 16th November 2023
Time: 14:00-15:30 GMT | 15:00-16:30 CET
Speakers: Alessandra Serra (Saryga / University of Cambridge), Sandrine Guilleminot (Servier), Nils Ternès (Sanofi), and Karl Köchert (Bayer AG).
Who is this event intended for? Everybody interested to learn more about the importance of biomarkers in clinical development.
What is the benefit of attending? Please join the discussion on how to improve clinical development using biomarkers.
This event is free to attend, for both Members and Non-Members of PSI.
To register your place for this event, please click here.
In this webinar, you will get to know how an innovative adaptive design can increase the probability of success of your early phase clinical trial as well as hear the latest and greatest of the Machine Learning workstream from the Biomarkers ESIG.
Presentation 1: A promising adaptive biomarker-based design strategy for early phase clinical trials
Alessandra Serra and Sandrine Guilleminot
Identifying predictive biomarkers is crucial in patient-centric clinical development. Enrichment strategies in late stages of drug development have been widely studied in the literature. However, implementing these strategies in early stages presents significant challenges due to the small sample size and numerous uncertainties that arise at this point in the development process. These uncertainties encompass biomarker (BMK) predictive value, cutoff value of the biomarker used to identify patients in the BMK-positive subgroup, the proportion of patients in the BMK-positive subgroup and the magnitude of the treatment effect in patients BMK-positive and BMK-negative. Early phase adaptive designs can improve trial efficiency by allowing for adaptions during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. Simulations show that the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion. Specifically, in the considered settings, gains up to 30% in the overall probability to hit the study success criteria at the end of the trial were achieved in comparison to a conventional design.
Presentation 2: Machine Learning as an enabler of precision medicine
Nils Ternès and Karl Köchert
Since the re-creation of the Biomarkers ESIG in 2022, people from different horizons and job titles have expressed some interest in machine learning (ML) and artificial intelligence (AI) methods applied to drug development, from research to clinical. With this fact and the increasing interest in ML/AI from the scientific community and beyond, a group of a dozen people was set-up in the past months with the ambition to create a cross-company best practices guidance on the use of AI/ML in drug development. The group started with some proactive joint discussions to better understand each other’s interest in this area and has already contributed to the review and feedback to FDA’s recent discussion paper on usage of AI/ML in drug development. Now, the group is in a highly dynamic ideation phase to identify and choose topics which have the potential to impact drug development, e.g., virtual twin (VT) technology, GxP compliant AI/ML, use of image-based or digital biomarkers.
|
Speaker |
Biography |
|
|
Alessandra is a Research Associate in the field of adaptive clinical trial designs at the MRC Biostatistics Unit (Cambridge, UK). She also provides private consultancy on clinical trial designs and analysis at Saryga. Alessandra has concluded her PhD at the MRC BSU in Cambridge working on adaptive designs and methods to improve the efficiency of drug development. |
|
|
Sandrine is the Head of the Translational Statistics Group at Servier R&D. Jointly with her team members, she provides advanced statistical support and strategic insight into preclinical/early clinical development phases across Servier’s programs in oncology, Inflammation & Immunology and Central Nervous System. Since 2016, she is also an active member of Societé Française de Statistique's Biopharmacy and Health group. Prior to joining Translational Medicine, Sandrine worked in Clinical Development at Fovea, Sanofi and Servier giving her a rich and successful history in biostatistic issues in drug development, including a track record of successful regulatory interactions with global health authorities. Her main research interests focus on quantitative decision making, innovative designs, predictive models, and BMK-driven strategies. |
|
|
Nils Ternès is a statistical biomarker leader at Sanofi R&D in France where he leads the biomarker-related statistical activities on several compounds in clinical development across all phases mostly in Oncology and Inflammation & Immunology. With this position, Nils is continuously looking for data and analytical methods innovations as well as operational efficiency in order to ensure effective decision making and increase the productivity of drug development. Before joining Sanofi, Nils studied statistics applied to public health at Paris-Saclay University (MSc) and holds a PhD in Biostatistics (2016) at Gustave Roussy cancer institute on advanced penalized regression techniques for the identification of prognostic and predictive biomarkers in high-dimensional settings. With a constant interest in learning and promoting the use of ML/AI technics to support clinical development, he is now co-leading the Machine Learning workstream from the Biomarkers ESIG. |
|
|
As Head of Biomarker & Data Insights at Bayer AG (Berlin, Germany) Karl leads a team of data scientists / statisticians. With a background in omics data science and precision medicine, his team’s major objective is to advance drug development by enabling holistic understanding of complex biological systems - namely the patients in need. In this vein, their current endeavour is to understand how applied AI/ML can help to detect highly complex safety and efficacy signals in interventional clinical trials and how that can be utilized as a basis for creating virtual twins of specific disease indications. Karl, being a Biochemist by training, discovered his passion for mathematical modelling of complex biological systems during his PhD at Humboldt University (Berlin, Germany) and subsequently devoted himself to applied machine learning during postdocs at TU-Dresden (Germany) and the Max-Delbrück-Center for Molecular Medicine (Berlin, Germany) before joining Bayer AG in 2014. At Bayer he has held positions of increasing responsibility as Study and Project Biomarker statistician for interventional trials of all phases in oncology. In August 2023 Karl has joined Niles Ternès as co-lead of the Machine Learning workstream from the Biomarker ESIG. |
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Who is this event intended for? Statisticians with an interest understanding dose-finding in oncology. What is the benefit of attending? Learn about the state of oncology dose finding, particularly in light of current FDA guidance.
The book club’s usual focus is to read and discuss professional development books. In this short format event you can more easily develop you career without the commitment of reading the whole book - simply listen to the 1-hour long podcast before joining the interactive session on 21 May.
This webinar is organised by the RWD SIG and the Historical Data SIG. We will review recent methods, applications, and tools of integrating subject-level-data from clinical trial with external data using Bayesian methods and/or causal inference methods.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This will be a 45 minute webinar which will explain the topic presented in the published paper, ‘Applying the Estimand Framework to Clinical Pharmacology Trials with a Case Study in Bioequivalance’. There will be 15 minutes for a panel Q&A with some of the authors following the presentation.
This will be a 45 minute webinar which will explain the topic presented in the published paper, ‘Applying the Estimand Framework to Clinical Pharmacology Trials with a Case Study in Bioequivalance’. There will be 15 minutes for a panel Q&A with some of the authors following the presentation.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
The Institute of Cancer Research are seeking to appoint a Research Group Leader to join The CRUK Clinical Trials and Statistics Unit at the ICR.
This is an exciting, new opportunity for an experienced Statistician looking to take the next step in their career. Offered as a remote or hybrid position aligned with our site in Harrogate, North Yorkshire.
The BioMarin internship programme will enable students to gain valuable experience and knowledge of the processes and systems within BioMarin, whilst gaining an insight into the pharmaceutical/biotech industry.
About cookies on this site
We use cookies to collect and analyse information on site performance and usage, to provide social media features and to enhance and customise content and advertisements.
About cookies on this site
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
CookieHub is a Consent Management Platform (CMP) which allows users to control storage and processing of personal information.
Cloudflare is a global network designed to make everything you connect to the Internet secure, private, fast, and reliable.
Amazon Web Services offers a broad set of global cloud-based products including compute, storage, databases, analytics, networking, mobile, developer tools, management tools, IoT, security, and enterprise applications.
Microsoft Azure is a cloud computing platform offering a wide range of services, including virtual machines, databases, and AI tools.
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic.
Vimeo, Inc. is an American video hosting, sharing, services provider, and broadcaster. Vimeo focuses on the delivery of high-definition video across a range of devices.
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them. When categories than have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. Additionally you can see a list of cookies assigned to each category and detailed information in the cookie declaration.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| ARRAffinity | .psiweb.org | Session | |
This cookie is set by websites run on the Windows Azure cloud platform. It is used for load balancing to make sure the visitor page requests are routed to the same server in any browsing session. | |||
| ARRAffinitySameSite | .psiweb.org | Session | |
Used to distribute traffic to the website on several servers in order to optimize response times. | |||
| __cf_bm | .vimeo.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| _cfuvid | .vimeo.com | Session | |
Used by Cloudflare WAF to distinguish individual users who share the same IP address and apply rate limits | |||
| __cf_bm | .glueup.com | Cloudflare, Inc. | 1 hour |
The __cf_bm cookie supports Cloudflare Bot Management by managing incoming traffic that matches criteria associated with bots. The cookie does not collect any personal data, and any information collected is subject to one-way encryption. | |||
| AWSALBTGCORS | psi.glueup.com | 7 days | |
AWS Classic Load Balancer Cookie: Load Balancing Cookie: Used to map the session to the instance. Same value as AWSELB. | |||
| PHPSESSID | psi.glueup.com | Session | |
Cookie generated by applications based on the PHP language. This is a general purpose identifier used to maintain user session variables. It is normally a random generated number, how it is used can be specific to the site, but a good example is maintaining a logged-in status for a user between pages. | |||
| History.store | Session | ||
| cookiehub | .psiweb.org | CookieHub | 365 days |
Used by CookieHub to store information about whether visitors have given or declined the use of cookie categories used on the site. | |||
Preferences
Preference cookies enables the web site to remember information to customize how the web site looks or behaves for each user. This may include storing selected currency, region, language or color theme.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| vuid | .vimeo.com | 400 days | |
These cookies are used by the Vimeo video player on websites. | |||
| AWSALBCORS | psi.glueup.com | 7 days | |
Amazon Web Services cookie. This cookie enables us to allocate server traffic to make the user experience as smooth as possible. A so-called load balancer is used to determine which server currently has the best availability. The information generated cannot identify you as an individual. | |||
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
| Name | Hostname | Vendor | Expiry |
|---|---|---|---|
| _ga_ | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics 4 to determine that two distinct hits belong to the same user across browsing sessions. | |||
| _ga | .psiweb.org | 400 days | |
Contains a unique identifier used by Google Analytics to determine that two distinct hits belong to the same user across browsing sessions. | |||
